Gracure Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Gracure Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $28.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Gracure Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $28.1M Trade | TransData Nexus

Gracure Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $28.1M Total Trade · DGFT Verified

Gracure Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $28.1M across 17 products in 9 therapeutic categories. Based on 1,272 verified export shipments from Indian Customs (DGFT) records, Gracure Pharmaceuticals Limited is the #1 Indian exporter in 1 product including Melatonin. Top exports include Tramadol ($5.6M), Albendazole ($4.2M), Folic ($3.0M).

Gracure Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Gracure Pharmaceuticals Limited pharmaceutical export portfolio — 17 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is Gracure Pharmaceuticals Limited? — Company Overview & Market Position

Gracure Pharmaceuticals Limited, established on June 1, 1992, is a Delhi-based pharmaceutical company specializing in the development and manufacturing of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24232DL1992PLC049002 and is registered with the Registrar of Companies, Delhi. As of January 5, 2026, Gracure's authorized capital stands at ₹5.25 crore, with a paid-up capital of ₹2.82 crore.

Headquartered at 251-254 IInd Floor, DLF Tower 15 Shivaji Marg, New Delhi, Delhi 110015, India, Gracure employs approximately 529 professionals. The company's website, www.gracure.com, provides comprehensive information about its products, services, and global reach.

What Does Gracure Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tramadol$5.6M 2Albendazole$4.2M

Product Portfolio — Top 17 by Export Value

Gracure Pharmaceuticals Limited exports 17 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tramadol	Analgesics & Antipyretics	$5.6M	124	1.5%	8
2	Albendazole	Antimalarial & Antiparasitic	$4.2M	175	5.8%	4
3	Folic	Nutritional Supplements	$3.0M	236	5.3%	2
4	Melatonin	Nutritional Supplements	$2.3M	78	24.8%	1
5	Celecoxib	Analgesics & Antipyretics	$1.9M	75	1.4%	15
6	Doxycycline	Antibiotics	$1.8M	51	1.5%	10
7	Fluconazole	Antifungals	$1.7M	178	1.9%	11
8	Sulfadoxine	Antimalarial & Antiparasitic	$1.6M	39	2.9%	3
9	Meloxicam	Analgesics & Antipyretics	$1.0M	40	0.5%	8
10	Chlorpheniramine	Antihistamines & Allergy	$990.1K	70	2.1%	7
11	Pyrimethamine	Antimalarial & Antiparasitic	$818.5K	29	1.8%	8
12	Dextromethorphan	Respiratory & OTC	$725.1K	51	4.9%	5
13	Captopril	Cardiovascular	$686.2K	31	5.5%	3
14	Spironolactone	Diuretics	$584.7K	16	0.3%	12
15	Ambroxol	Respiratory & OTC	$470.8K	19	3.2%	7
16	Ketoconazole	Antifungals	$423.8K	42	1.1%	13
17	Bromhexine	Respiratory & OTC	$254.0K	18	1.6%	13

Gracure Pharmaceuticals Limited exports 17 pharmaceutical products across 9 therapeutic categories with a total export value of $28.1M. The company is the #1 Indian exporter in 1 product: Melatonin. The top category is Analgesics & Antipyretics (30.3% of portfolio), followed by Antimalarial & Antiparasitic (23.6%), indicating a concentrated portfolio with the top 5 products accounting for 60.5% of total export value.

Gracure Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Gracure Pharmaceuticals operates two manufacturing facilities in India, each designed to meet international regulatory standards. The first facility, spanning 8,000 square meters, is approved by EU-GMP, TGA Australia, SAUMP Ukraine, FDA Philippines, and FMHACA Ethiopia. It is capable of producing tablets, hard gelatin capsules, oral liquids, dry powder syrups, stick packs, and semi-solid external preparations.

The second facility, covering 3,300 square meters, complies with regulated market standards and is equipped with state-of-the-art equipment. This facility focuses on manufacturing tablets and oral liquids.

3Key Leadership

The leadership team at Gracure Pharmaceuticals is headed by Mr. A.S. Bhargava, the founder and Managing Director, who has over 40 years of experience in the pharmaceutical industry. Mr. Parag Bhargava serves as the Director of Quality & Business Development, overseeing operational planning and analysis. Mrs. Sheere Bhargava, Associate Director, brings dynamic leadership and strategic foresight to the organization.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Gracure Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Gracure Pharmaceuticals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by international regulatory bodies such as EU-GMP, TGA Australia, and WHO-GMP, facilitating market access in these regions. While specific details regarding regulatory filings, approvals, and market access status in the U.S., EU, UK, Australia, and Japan are not publicly disclosed, the company's adherence to international standards positions it favorably for entry into these markets.

2Emerging Markets

Gracure Pharmaceuticals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are delivered across the globe in over 25 countries, including Vietnam, Cambodia, Laos, Malaysia, Singapore, Hong Kong, Myanmar, Ethiopia, Peru, the Philippines, Sri Lanka, Guatemala, Mozambique, Nigeria, Afghanistan, Mali, Chile, Yemen, Nepal, Bhutan, Zimbabwe, Botswana, Kenya, Costa Rica, New Zealand, and Australia. The company's WHO-GMP certification enhances its credibility and facilitates access to these markets.

3Geographic Strategy

Gracure Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Gracure Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's adherence to international regulatory standards, such as WHO-GMP, TGA Australia, and EU-GMP, indicates a commitment to quality and regulatory compliance, which is essential for FDA approvals.

2WHO & EU GMP

Gracure Pharmaceuticals holds WHO-GMP certification, reflecting its compliance with international manufacturing standards. The company's manufacturing facilities are also approved by EU-GMP, TGA Australia, and SAUMP Ukraine, indicating a broad acceptance of its quality standards by various regulatory bodies.

3CDSCO & Indian Regulatory

Gracure Pharmaceuticals operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly disclosed.

Gracure Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Gracure Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. While specific market share comparisons are not publicly available, the company's adherence to international regulatory standards, such as WHO-GMP, TGA Australia, and EU-GMP, positions it favorably in the market.

2Key Differentiators

Gracure Pharmaceuticals' key differentiators include its extensive product portfolio, adherence to international regulatory standards, and a strong presence in both regulated and emerging markets. The company's WHO-GMP certification and approvals from regulatory bodies such as TGA Australia and EU-GMP underscore its commitment to quality and compliance.

3Strategic Position

Gracure Pharmaceuticals is strategically positioned as a research-driven pharmaceutical company with a focus on the development and manufacturing of finished pharmaceutical formulations. The company's adherence to international regulatory standards and its global reach reflect a strategic direction aimed at expanding its presence in both regulated and emerging markets.

Buyer Due Diligence Brief — Evaluating Gracure Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Gracure Pharmaceuticals demonstrates a strong track record in manufacturing and exporting pharmaceutical products. The company's adherence to international regulatory standards, such as WHO-GMP, TGA Australia, and EU-GMP, indicates reliability and consistency in product quality. Specific details regarding export volume and consistency are not publicly disclosed.

2Certifications to Verify

Importers should verify the following certifications when considering Gracure Pharmaceuticals as a supplier:

WHO-GMP Certification: Confirms compliance with World Health Organization Good Manufacturing Practices. Verification can be done through the WHO official website or by contacting the company directly.

EU-GMP Certification: Indicates adherence to European Union Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to Gracure Pharmaceuticals.

Frequently Asked Questions — Gracure Pharmaceuticals Limited

How many pharmaceutical products does Gracure Pharmaceuticals Limited export from India?

Gracure Pharmaceuticals Limited exports 17 pharmaceutical products across 9 therapeutic categories. The top exports are Tramadol ($5.6M), Albendazole ($4.2M), Folic ($3.0M), Melatonin ($2.3M), Celecoxib ($1.9M). Total export value is $28.1M.

What is Gracure Pharmaceuticals Limited's total pharmaceutical export value?

Gracure Pharmaceuticals Limited's total pharmaceutical export value is $28.1M, based on 1,272 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Gracure Pharmaceuticals Limited the #1 Indian exporter?

Gracure Pharmaceuticals Limited is the #1 Indian exporter in 1 products: Melatonin (24.8% market share).

What therapeutic categories does Gracure Pharmaceuticals Limited cover?

Gracure Pharmaceuticals Limited exports across 9 therapeutic categories. The largest are Analgesics & Antipyretics (30.3%, 3 products), Antimalarial & Antiparasitic (23.6%, 3 products), Nutritional Supplements (18.9%, 2 products).

Get Full Gracure Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.